Advanced search
1 file | 261.66 KB

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

(2010) ANNALS OF ONCOLOGY. 21(10). p.1967-1973
Author
Organization
Abstract
Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL. Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum-fluorouracil plus cetuximab were not significantly worse than those for platinum-fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating). Conclusion: Adding cetuximab to platinum-fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN.
Keywords
TRIAL, QLQ-H-AND-N35, COLORECTAL-CANCER, recurrent and metastatic, quality of life, head and neck cancer, cetuximab, cisplatin, RADIOTHERAPY, COMBINATION, CISPLATIN, SURVIVAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 261.66 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Mesía, R, F Rivera, A Kawecki, Sylvie Rottey, R Hitt, H Kienzer, D Cupissol, et al. 2010. “Quality of Life of Patients Receiving Platinum-based Chemotherapy Plus Cetuximab First Line for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck.” Annals of Oncology 21 (10): 1967–1973.
APA
Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., et al. (2010). Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANNALS OF ONCOLOGY, 21(10), 1967–1973.
Vancouver
1.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANNALS OF ONCOLOGY. 2010;21(10):1967–73.
MLA
Mesía, R, F Rivera, A Kawecki, et al. “Quality of Life of Patients Receiving Platinum-based Chemotherapy Plus Cetuximab First Line for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck.” ANNALS OF ONCOLOGY 21.10 (2010): 1967–1973. Print.
@article{1195838,
  abstract     = {Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H\&N35) module were used to assess QoL.
Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H\&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum-fluorouracil plus cetuximab were not significantly worse than those for platinum-fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H\&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating).
Conclusion: Adding cetuximab to platinum-fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN.},
  author       = {Mes{\'i}a, R and Rivera, F and Kawecki, A and Rottey, Sylvie and Hitt, R and Kienzer, H and Cupissol, D and De Raucourt, D and Benasso, M and Koralewski, P and Delord, JP and Bokemeyer, C and Curran, D and Gross, A and Vermorken, JB},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  language     = {eng},
  number       = {10},
  pages        = {1967--1973},
  title        = {Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck},
  url          = {http://dx.doi.org/10.1093/annonc/mdq077},
  volume       = {21},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: